Leading researchers from around the world will gather for the annual meeting of the European Association for the Study of Diabetes (EASD). At this year’s meeting, which will take place virtually from September 27-October 1, more than 40 studies will be presented by Breakthrough T1D researchers, funded now or in the past, working to find cures for type 1 diabetes (T1D) and improve the lives of those living with the disease today.
- Chantal Mathieu, M.D., Ph.D., will present on the clinical trial that tested AG019, an immune-modulating therapy, alone or with teplizumab, an anti-CD3 therapy, in recent-onset T1D (a side note: Kevan Herold, M.D., was also a principal investigator on the study), suggesting that AG019 could be effective in preserving insulin production. In addition, AG019 has the convenience of being taken orally.
- JDRF-funded Hypo-RESOLVE (Hypoglycemia—REdefining SOLutions for better liVEs), an international consortium of 23 public and private organizations, has preliminary results from its effort to understand low blood sugar, called hypoglycemia, and its impact on people with T1D, from its pooled database of dozens of clinical trials.
- JDRF-funded Carmella Evans-Molina, M.D., Ph.D., Roberto Mallone, M.D., Ph.D., and Raghu Mirmira, M.D., Ph.D., will discuss the role of beta cells and how they contribute to T1D, in an EASD/Breakthrough T1D Symposium: Beta cell (dys)function, on which Breakthrough T1D CEO, Aaron J. Kowalski, Ph.D., and Breakthrough T1D-grantee, Sarah Richardson, Ph.D., are chairs.
- A novel dual-hormone artificial pancreas for T1D will be presented by Ahmad Haidar, Ph.D., a former Breakthrough T1D-funded postdoctoral fellow and grantee for clinical trials of his insulin plus pramlintide—a synthetic hormone engineered to closely resemble another hormone which is produced by beta cells, amylin—artificial pancreas system.
Keep up with the latest updates and exciting news from the EASD Conference on Twitter, at @JDRFResearch.
